絞り込み

16752

広告

A study of docetaxel and irinotecan in children and young adults with recurrent or refractory Ewing sarcoma family of tumors.

著者 Yoon JH , Kwon MM , Park HJ , Park SY , Lim KY , Joo J , Park BK
BMC Cancer.2014 Aug 28 ; 14():622.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (4view , 0users)

Full Text Sources

Medical

Miscellaneous

Patients with Ewing sarcoma family of tumors (ESFT) who are resistant even to salvage chemotherapy, have dismal prognoses and few therapeutic options. Because the docetaxel/irinotecan (DI) combination has not been previously evaluated in ESFT, we prospectively evaluated its use in patients with recurrent or refractory ESFT.
PMID: 25164234 [PubMed - indexed for MEDLINE]
印刷用ページを開く Endnote用テキストダウンロード